| Paroxysmal nocturnal hemoglobinuria
PiaSky vs Ultomiris
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Piasky vs Ultomiris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltomiris has a higher rate of injection site reactions vs Piasky based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultomiris but not Piasky, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Piasky
Ultomiris
At A Glance
IV infusion / SC injection
Every 4 weeks (maintenance)
Complement C5 inhibitor
IV infusion
Every 4-8 weeks
C5 complement inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Paroxysmal nocturnal hemoglobinuria Loading: 1,000 mg (>=40 kg to <100 kg) or 1,500 mg (>=100 kg) IV on Day 1, then 340 mg SUBQ on Days 2, 8, 15, and 22; maintenance 680 mg (>=40 kg to <100 kg) or 1,020 mg (>=100 kg) SUBQ every 4 weeks starting Day 29.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Known serious hypersensitivity reaction to crovalimab or any excipient
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=10%) Infusion-related reaction, respiratory tract infection, viral infection, Type III hypersensitivity reaction, peripheral edema, headache
Serious Epistaxis, pneumonia, infusion-related reaction, pyelonephritis, COVID-19, hypovolemic shock, nasopharyngitis, urinary tract infection
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Pharmacology
Crovalimab-akkz is a humanized IgG1 monoclonal antibody that binds with high affinity to complement protein C5, inhibiting its cleavage into C5a and C5b and preventing formation of the membrane attack complex (MAC), thereby inhibiting terminal complement-mediated intravascular hemolysis in patients with PNH.
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Piasky
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Piasky
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Piasky
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ultomiris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PiaskyView full Piasky profile
UltomirisView full Ultomiris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.